Partnerships for better neglected disease drug discovery and development: how have we fared?

References

• Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing the chronic pandemic. Lancet. 2017;389(10066):312–325.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second WHO Rep neglected Trop Dis. 2013;3(9):67–71.
   Google Scholar
• Herricks JR, Hotez PJ, Wanga V, et al. The global burden of disease study 2013: what does it mean for the NTDs? PLoS Negl Trop Dis. 2017;11(8):1–21.
   Web of Science ®Google Scholar
• Houweling TAJ, Karim-Kos HE, Kulik MC, et al. Socioeconomic inequalities in neglected tropical diseases: a systematic review. PLoS Negl Trop Dis. 2016;10(5):e0004546.
   PubMed Web of Science ®Google Scholar
• MSF. Lives on the edge: time to align medical research and patients’ needs. Geneva, Switzerland: Médecins Sans Frontieres Access Campaign; 2016.
   Google Scholar
• Moon S, Bermudez J, ’T Hoen E. Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? PLoS Med. 2012;9. DOI:10.1371/journal.pmed.1001218
   Web of Science ®Google Scholar
• Trouiller P, Olliaro P, Torreele E, et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002;359(9324):2188–2194.
   PubMed Web of Science ®Google Scholar
• Pedrique B, Strub-Wourgaft N, Some C, et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Heal. 2013;1(6):371–379.
   PubMed Web of Science ®Google Scholar
• Ferreira L, Andricopulo AD. Drugs and vaccines in the 21st century for neglected diseases. Lancet Infect Dis. 2019;19(2):125–127.
   PubMed Web of Science ®Google Scholar
• Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2005;2:0828–0832.
   Web of Science ®Google Scholar
• Aerts C, Sunyoto T, Tediosi F, et al. Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy (New York). 2017;121(7):745–754.
   PubMed Web of Science ®Google Scholar
• Roehrich JK, Lewis MA, George G. Are public–private partnerships a healthy option? A systematic literature review. Soc Sci Med. 2014;113:110–119.
   PubMed Web of Science ®Google Scholar
• Scannell J, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;1(3):191–200.
   Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185.
   PubMed Web of Science ®Google Scholar
• MSF. Fatal imbalance: the crisis in research and development for drugs for neglected diseases. Geneva, Switzerland: Médecins Sans Frontieres Access Campaign; 2001.
   Google Scholar
• Pecoul B, Chirac P, Trouiller P, et al. Access to essential drugs in poor countries. Virtual Mentor. 2000;2:361–367.
   Google Scholar
• Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination. Report of the Consultative Working Group on Research and Development: Financing and Coordination. Geneva, Switzerland: World Health Organization; 2012;238. ISBN 978 92 4 1503457.
   Google Scholar
• Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ. 2001;79(8):735–741.
   PubMed Web of Science ®Google Scholar
• Mueller-Langer F. Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research? Health Econ Policy Law. 2013;8(2):185–208.
   PubMed Web of Science ®Google Scholar
• Jain N, Hwang T, Franklin JM, et al. Association of the priority review voucher with neglected tropical disease drug and vaccine development. Jama. 2017;318(4):388.
   PubMed Web of Science ®Google Scholar
• Widdus RWHite K. Combating diseases associated with poverty: financing strategies for product development and the potential role of public private partnerships. Private Partnerships for Health. Geneva, Switzerland: Initiative Public-Private Partnership for Health; 2004. p. 42
   Google Scholar
• Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov. 2003;2(11):919–928.
   PubMed Web of Science ®Google Scholar
• Yildirim O, Gottwald M, Schüler P, et al. Opportunities and challenges for drug development: public–private partnerships, adaptive designs and big data. Front Pharmacol. 2016;7. DOI:10.3389/fphar.2016.00461
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):1–5.
   Web of Science ®Google Scholar
• Dahlin JL, Inglese J, Walters MA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov. Nature Publishing Group. 2015;14(4):279–294.
   PubMed Web of Science ®Google Scholar
• Preston S, Gasser RB. Working towards new drugs against parasitic worms in a public-development partnership. Trends Parasitol. 2018;34(1):4–6.
   PubMed Web of Science ®Google Scholar
• Alcântara LM, Ferreira TCS, Gadelha FR, et al. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Int J Parasitol Drugs Drug Resist. 2018;8:430–439.
   PubMed Web of Science ®Google Scholar
• Chan HT, Atun FRCP R, Bärnighausen T, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy Executive summary. Lancet Diabetes Endocrinol. 2017. DOI:10.1016/S2213-8587(17)30181-X.
   Web of Science ®Google Scholar
• Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov. 2014;13(8):588–602.
   PubMed Web of Science ®Google Scholar
• Chatelain E, Konar N. Translational challenges of animal models in chagas disease drug development: A review. Drug Des Devel Ther. Dove Medical Press Ltd. 2015:4807–4823. DOI:10.2147/DDDT.S90208
   PubMed Web of Science ®Google Scholar
• Loría-Cervera EN, Andrade-Narváez FJ. Review: animal models for the study of leishmaniasis immunology. Rev Inst Med Trop Sao Paulo. Instituto de Medicina Tropical de Sao Paulo. 2014;56(1):1–11.
   PubMed Web of Science ®Google Scholar
• Palmer M, Chaguturu R. Academia-pharma partnerships for novel drug discovery: essential or nice to have? Expert Opin Drug Discov. 2017;12(6):537–540.
   PubMed Web of Science ®Google Scholar
• Allarakhia M, Ajuwon L. Understanding and creating value from open source drug discovery for neglected tropical diseases. Expert Opin Drug Discov. 2012;7(8):643–657.
   PubMed Web of Science ®Google Scholar
• Kameda K. Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil. Dev World Bioeth. 2014;14(2):101–108.
   PubMed Web of Science ®Google Scholar
• Reeder JC. TDR: (Back) Making a Difference. PLoS Negl Trop Dis. 2014;8:2.
   Web of Science ®Google Scholar
• Õmura S, Crump A. The life and times of ivermectin - A success story. Nat Rev Microbiol. 2004;2(12):984–989.
   PubMed Web of Science ®Google Scholar
• Engel J. Miltefosine, the story of a successful partnership: disease endemic country - TDR - pharmaceutical industry (Zentaris). TDR News. 2002;68:5.
   Google Scholar
• Gutteridge WE. TDR collaboration with the pharmaceutical industry. Trans R Soc Trop Med Hyg. 2006;100. DOI:10.1016/j.trstmh.2006.02.013
   Web of Science ®Google Scholar
• Ogundahunsi OAT, Vahedi M, Kamau EM, et al. Strengthening research capacity—TDR’s evolving experience in low- and middle-income countries. PLoS Negl Trop Dis. 2015;9. DOI:10.1371/journal.pntd.0003380.
   Web of Science ®Google Scholar
• Ridley RG, Fletcher ER. Making a difference: 30 years of TDR. Nat Rev Microbiol. 2008;6(5):401–407.
   PubMed Web of Science ®Google Scholar
• Van Voorhis WC, Adams JH, Adelfio R, et al. Open source drug discovery with the malaria box compound collection for neglected diseases and beyond. PLoS Pathog. 2016;12(7):e1005763.
   PubMed Web of Science ®Google Scholar
• Duffy S, Sykes ML, Jones AJ, et al. Screening the medicines for malaria venture pathogen box across multiple pathogens reclassifies starting points for open-source drug discovery. Antimicrob Agents Chemother. 2017;61. DOI:10.1128/AAC.00379-17.
   Web of Science ®Google Scholar
• Drugs for Neglected Diseases Initiative. an innovative approach to R&D for neglected patients: ten years of experience & lessons learned by DNDi. Geneva, Switzerland; 2014.
   Google Scholar
• DNDi 2018 annual report. [cited 2019 Nov 21]. Available from: https://www.dndi.org/annualreport2018/
   Google Scholar
• Gottwald M, Becker A, Bahr I, et al. Public-private partnerships in lead discovery: overview and case studies. Arch Pharm (Weinheim). 2016;349(9):692–697.
   PubMed Web of Science ®Google Scholar
• Goldman M, Seigneuret N, Eichler H-G. The innovative medicines initiative: an engine for regulatory science. Nat Rev Drug Discov. 2015;14(1):1–2.
   PubMed Web of Science ®Google Scholar
• Manner CK, Graef KM, Dent J. WIPO Re:search: catalyzing public-private partnerships to accelerate tropical disease drug discovery and development. Trop Med Infect Dis. 2019;4:53.
   Google Scholar
• Ramamoorthi R, Graef KM, Dent J. WIPO Re:search: accelerating anthelmintic development through cross-sector partnerships. Int J Parasitol Drugs Drug Resist. 2014;4:220–225.
   PubMed Web of Science ®Google Scholar
• Thomas CJ, McKew JC. Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government. Curr Top Med Chem. United Arab Emirates. 2014;14(3):291–293.
   PubMed Web of Science ®Google Scholar
• Bombelles T, Coaker H. Neglected tropical disease research: rethinking the drug discovery model. Future Med Chem. England. 2015:693–700. DOI:10.4155/fmc.15.29
   PubMed Web of Science ®Google Scholar
• Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006;5(11):941–955.
   PubMed Web of Science ®Google Scholar
• Fagnan DE, Yang NN, McKew JC, et al. Financing translation: analysis of the NCATS rare-diseases portfolio. Sci Transl Med. American Association for the Advancement of Science. 2015. DOI:10.1126/scitranslmed.aaa2360
   PubMed Web of Science ®Google Scholar
• Drug repurposing screening for rare and neglected diseases | National center for advancing translational sciences. [cited 2019 Nov 21]. Available from: https://ncats.nih.gov/trnd/projects/drug-repurposing
   Google Scholar
• Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144–154.
   PubMed Web of Science ®Google Scholar
• Pelfrene E, Harvey Allchurch M, Ntamabyaliro N, et al. The European medicines agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Negl Trop Dis. 2019;13(6):e0007381.
   PubMed Web of Science ®Google Scholar
• Said M, Zerhouni E. The role of public-private partnerships in addressing the biomedical innovation challenge. Nat Rev Drug Discov. Nature Publishing Group. 2014;13(11):789–790.
   PubMed Web of Science ®Google Scholar
• Matter A, Keller T. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions. Drug Discov Today. 2008;13(7–8):347–352.
   PubMed Web of Science ®Google Scholar
• Jakobsen PH, Wang M-W, Nwaka S. Innovative partnerships for drug discovery against neglected diseases. PLoS Negl Trop Dis. 2011;5(9):e1221.
   PubMed Web of Science ®Google Scholar
• United Nations Development Programme. A pipeline analysis of new products for malaria, tuberculosis and neglected tropical diseases.  New York: United Nations Development Programme; 2016.
   Google Scholar
• De Pinho Campos K, Norman CD, Jadad AR. Product development public-private partnerships for public health: a systematic review using qualitative data. Soc Sci Med. 2011;73(7):986–994. .
   PubMed Web of Science ®Google Scholar
• Croft SL. Public-private partnership: from there to here. Trans R Soc Trop Med Hyg. 2005;99:S9–14.
   PubMed Web of Science ®Google Scholar
• Weng HB, Chen HX, Wang MW. Innovation in neglected tropical disease drug discovery and development. Infect Dis Poverty. 2018;7:1–9.
   PubMed Web of Science ®Google Scholar
• Ekins S, Waller CL, Bradley MP, et al. Four disruptive strategies for removing drug discovery bottlenecks. Drug Discov Today. 2013;18(5–6):265–271.
   PubMed Web of Science ®Google Scholar
• Casty FE, Wieman MS. Drug development in the 21st century: the synergy of public, private, and international collaboration. Ther Innov Regul Sci. 2013;47:375–383.
   PubMed Web of Science ®Google Scholar
• Fonteilles-Drabek S, Reddy D, Wells TNC. Managing intellectual property to develop medicines for the world’s poorest. Nat Rev Drug Discov. 2017;16:223–224.
   PubMed Web of Science ®Google Scholar
• Ferrins L, Pollastri MP. The importance of collaboration between industry, academics, and nonprofits in tropical disease drug discovery. ACS Infect Dis. 2018;4(4):445–448.
   PubMed Web of Science ®Google Scholar
• Watts G. Drug development partnerships look set to grow. Lancet. England. 2016;388(10039):16–18.
   PubMed Web of Science ®Google Scholar
• Chapman N, Doubell A, Oversteegen L, et al. Neglected disease research and development: reaching new heights. GFINDER Rep. 2018;2019:1–41.
   Google Scholar
• Nayak RK, Avorn J, Kesselheim AS. Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ. 2019;367. DOI:10.1136/bmj.l5766
   Google Scholar
• Kirk K, Hamelmann L, Halawi F, et al. Report of the United Nations secretary-general’s high-level panel on access to medicines. New York: United Nation's Secretary General Office; 2016. p. 70.
   Google Scholar
• Special Program in Research and Training in Tropical Diseases, World Health Organization. TDR | Health product research and development fund: a proposal for financing and operation. Geneva, Switzerland: WHO; 2019.
   Google Scholar
• Terry RF, Yamey G, Miyazaki-Krause R, et al. Funding global health product R&D: the portfolio-to-impact model (P2I), a new tool for modelling the impact of different research portfolios. Gates Open Res. 2018;2.
   PubMedGoogle Scholar
• Young R, Bekele T, Gunn A, et al. Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Res. 2018;2:23.
   PubMedGoogle Scholar